Brad Miller, Moderna's CIO, has driven technology innovation to help drive continued gains for the roughly $7 billion revenue ...

Coegi used more than 500 million impressions and paid social optimized with attention and emotion metrics to drive 24% of ...

Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of ...

“a better dengue vaccine” While the DOH has avoided or chose not to post statistics on monthly active cases of dengue and dengue-related mortality, they have recently advised the public to be vigilant ...

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

The Cambridge-based company’s latest COVID shot was approved three weeks earlier than last year, according to a statement ...

Moderna posted a surprising third-quarter profit, driven by cost-cutting and higher-than-expected Covid vaccine sales.

Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.

Reports third quarter revenues of $1.9 billion, GAAP net income of $13 million and GAAP EPS of $0.03Achieves year-to-date product sales of $2.2 ...

Moderna’s COVID-19 vaccine will soon have a figurative “made in North Carolina” stamp. Thermo Fisher Scientific, a contract manufacturer of pharmaceuticals, will begin making “hundreds of millions of ...

Healthcare is possibly the most overlooked of all the mega-trends. But this may leave investors with more opportunities once ...